Type 2 diabetes Trials in Mérida, Mexico
Conditions / Type 2 diabetes / Mérida, Mexico
Type 2 diabetes is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00683878 | Add-on to Thiazolidinedione (TZD) Failures | COMPLETED | PHASE3 |
| NCT00528372 | A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise | COMPLETED | PHASE3 |
| NCT05662332 | A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) | COMPLETED | PHASE3 |
| NCT01195662 | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication | COMPLETED | PHASE3 |
| NCT02725593 | Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years | COMPLETED | PHASE3 |
| NCT01606007 | Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT01609582 | Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease | TERMINATED | PHASE3 |
| NCT06297603 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00643851 | An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets | COMPLETED | PHASE3 |
| NCT01137474 | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker | COMPLETED | PHASE3 |